Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $1.1 million.

  • Biodesix's Share-based Compensation fell 30.50% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 32.93%. This contributed to the annual value of $6.6 million for FY2024, which is 23.54% up from last year.
  • Latest data reveals that Biodesix reported Share-based Compensation of $1.1 million as of Q3 2025, which was up 1.35% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Share-based Compensation peaked at $2.6 million during Q1 2024, and registered a low of $539,000 during Q2 2021.
  • Its 3-year average for Share-based Compensation is $1.4 million, with a median of $1.1 million in 2023.
  • Data for Biodesix's Share-based Compensation shows a peak YoY increase of 1,286.00% (in 2021) and a maximum YoY decrease of 64.35% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Biodesix's Share-based Compensation stood at $1.3 million in 2021, then skyrocketed by 63.93% to $2.1 million in 2022, then plummeted by 47.95% to $1.1 million in 2023, then increased by 17.02% to $1.3 million in 2024, then crashed by 30.50% to $1.1 million in 2025.
  • Its Share-based Compensation stands at $1.1 million for Q3 2025, versus $1.0 million for Q2 2025 and $972,000 for Q1 2025.